BR0110098A - Polynucleotide, recombinant genetic construct, expression vector, host cell, transgenic animal, peptide, methods for screening an agent for pharmacological activity, inhibiting the binding of gnrh to its native receptor in vivo, and contraception, and uses of type ii gnrh-r or an extracellular domain thereof - Google Patents

Polynucleotide, recombinant genetic construct, expression vector, host cell, transgenic animal, peptide, methods for screening an agent for pharmacological activity, inhibiting the binding of gnrh to its native receptor in vivo, and contraception, and uses of type ii gnrh-r or an extracellular domain thereof

Info

Publication number
BR0110098A
BR0110098A BR0110098-0A BR0110098A BR0110098A BR 0110098 A BR0110098 A BR 0110098A BR 0110098 A BR0110098 A BR 0110098A BR 0110098 A BR0110098 A BR 0110098A
Authority
BR
Brazil
Prior art keywords
gnrh
type
polynucleotide
peptide
screening
Prior art date
Application number
BR0110098-0A
Other languages
Portuguese (pt)
Inventor
Robert Peter Millar
Steven Lowe
Darrel Conklin
Original Assignee
Medical Res Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0009269A external-priority patent/GB0009269D0/en
Priority claimed from GB0014761A external-priority patent/GB0014761D0/en
Application filed by Medical Res Council filed Critical Medical Res Council
Publication of BR0110098A publication Critical patent/BR0110098A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

POLINUCLEOTìDEO, CONSTRUçãO GENéTICA RECOMBINANTE, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, ANIMAL TRANSGêNICO, PEPTìDEO, MéTODOS PARA TRIAGEM DE UM AGENTE QUANTO à ATIVIDADE FARMACOLóGICA, DE INIBIR A LIGAçãO DO GnRH A SEU RECEPTOR NATIVO IN VIVO, E DE CONTRACEPçãO, E, USOS DO GnRH-R DO TIPO II OU DE UM SEU DOMìNIO EXTRACELULAR. São providos polinucleotídeos codificando a sequência completa para os receptores de hormónios de liberação da gonadotropina do Tipo II de sagui e de seres humanos (GnRH-R Tipo II). As sequências de aminoácidos correspodentes são também providas.POLYNUCLEOTIDE, RECOMBINANT GENETIC CONSTRUCTION, EXPRESSION VECTOR, HOST CELL, TRANSGENIC ANIMAL, PEPTIDE, METHODS FOR SCREENING AN AGENT, PHARMACOLOGICAL ACTIVITY, INHIBITION OF THE INCEPTION AND GON INPRODUCTION, GnRH-R OF TYPE II OR AN EXTRACELLULAR DOMAIN. Polynucleotides encoding the full sequence for marmoset and human Type II gonadotropin releasing hormone receptor (GnRH-R Type II) are provided. Corresponding amino acid sequences are also provided.

BR0110098-0A 2000-04-15 2001-04-17 Polynucleotide, recombinant genetic construct, expression vector, host cell, transgenic animal, peptide, methods for screening an agent for pharmacological activity, inhibiting the binding of gnrh to its native receptor in vivo, and contraception, and uses of type ii gnrh-r or an extracellular domain thereof BR0110098A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0009269A GB0009269D0 (en) 2000-04-15 2000-04-15 Receptor
GB0014761A GB0014761D0 (en) 2000-06-17 2000-06-17 Receptor
US21523200P 2000-06-30 2000-06-30
PCT/GB2001/001755 WO2001078796A1 (en) 2000-04-15 2001-04-17 Type ii gonadotropin-releasing hormone receptor and polynucleotides encoding therefor

Publications (1)

Publication Number Publication Date
BR0110098A true BR0110098A (en) 2003-01-14

Family

ID=27255670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0110098-0A BR0110098A (en) 2000-04-15 2001-04-17 Polynucleotide, recombinant genetic construct, expression vector, host cell, transgenic animal, peptide, methods for screening an agent for pharmacological activity, inhibiting the binding of gnrh to its native receptor in vivo, and contraception, and uses of type ii gnrh-r or an extracellular domain thereof

Country Status (11)

Country Link
EP (1) EP1337282A2 (en)
JP (1) JP2003530837A (en)
KR (1) KR20020097218A (en)
AU (1) AU2001248599A1 (en)
BR (1) BR0110098A (en)
CA (1) CA2404127A1 (en)
HU (1) HUP0301666A2 (en)
IL (1) IL152011A0 (en)
NO (1) NO20024937L (en)
PL (1) PL357684A1 (en)
WO (1) WO2001078796A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281882A1 (en) * 2000-06-26 2002-01-08 Bayer Aktiengesellschaft Regulation of human gonadotropin releasing hormone receptor-like g protein-coupled receptor
AU2002249304A1 (en) * 2001-03-01 2002-09-19 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Novel human gnrh receptor
US20050282745A1 (en) * 2001-08-28 2005-12-22 Siler-Khodr Theresa M Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
WO2004010145A2 (en) * 2002-07-22 2004-01-29 Ardana Bioscience Limited Screening method
AU2003269087A1 (en) * 2002-07-22 2004-02-09 Ardana Bioscience Limited Gnrh modulator
PT1512016E (en) 2002-07-22 2006-06-30 Ardana Bioscience Ltd METHOD OF RESEARCH AND ANTITUMORAL PHARMACY CANDIDATE OBTAINED FROM THE SAME
KR101038183B1 (en) * 2010-12-27 2011-06-01 강범준 Waveblock and a covering method of the incline plane using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994000590A1 (en) * 1992-06-23 1994-01-06 The Mt. Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
AU2001248599A1 (en) 2001-10-30
NO20024937L (en) 2002-12-09
NO20024937D0 (en) 2002-10-14
WO2001078796A1 (en) 2001-10-25
KR20020097218A (en) 2002-12-31
PL357684A1 (en) 2004-07-26
IL152011A0 (en) 2003-04-10
EP1337282A2 (en) 2003-08-27
HUP0301666A2 (en) 2003-08-28
WO2001078796A3 (en) 2003-04-24
CA2404127A1 (en) 2001-10-25
WO2001078796A9 (en) 2002-02-28
JP2003530837A (en) 2003-10-21

Similar Documents

Publication Publication Date Title
BR0113921A (en) nucleic acids and receptor polypeptides
AR006188A1 (en) "PHARMACEUTICAL COMPOSITION TO INHIBIT SERINPROTEASE ACTIVITY, IN VITRO METHOD TO INHIBIT SERINPROTEASE ACTIVITY AND METHOD TO PREPARE SUCH COMPOSITION".
Fischer-Colbrie et al. Sequence analysis, tissue distribution and regulation by cell depolarization, and second messengers of bovine secretogranin II (chromogranin C) mRNA.
PH12013502425A1 (en) Smoothened polypeptides and methods of use
WO2004069876A3 (en) Trimeric polypeptide construct to induce an enduring t cell response
ATE445704T1 (en) EXPRESSION VECTOR FOR ANIMAL CELLS
ATE404583T1 (en) FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY
Albert et al. Direct synthesis of [DOTA-DPhe1]-octreotide and [DOTA-DPhe1, Tyr3]-octreotide (SMT487): two conjugates for systemic delivery of radiotherapeutical nuclides to somatostatin receptor positive tumors in man
BR0110098A (en) Polynucleotide, recombinant genetic construct, expression vector, host cell, transgenic animal, peptide, methods for screening an agent for pharmacological activity, inhibiting the binding of gnrh to its native receptor in vivo, and contraception, and uses of type ii gnrh-r or an extracellular domain thereof
ATE293169T1 (en) LATENCY ASSOCIATED PEPTIDES OF TGF-BETA TO MAKE PHARMACEUTICALLY ACTIVE PROTEINS LATENCY
KR960704932A (en) SINGLE-CHAIN FORMS OF THE GLYCOPROTEIN HORMONE QUARTET
Yotov et al. Nucleotide sequence of a mouse cDNA encoding the nonhistone chromosomal high mobility group protein-1 (HMG1).
Eberle Proopiomelanocortin and the melanocortin peptides
WO2002050111A3 (en) Isolated laminin 10
BR9812138A (en) Methods and compositions for therapies employing genes encoding secreted proteins such as interferon-beta
ATE357526T1 (en) MODIFIED HCV PEPTIDE VACCINES
ATE364392T1 (en) LIGAND/LYTIC PETIDE COMPOSITION AND USE THEREOF
ATE294816T1 (en) NEW, PHYSIOLOGICALLY ACTIVE PEPTIDES AND THEIR USE.
WO2002070657A8 (en) 93870, a human g-protein coupled receptor and uses therefor
PT1095143E (en) Inhibitor for diagnosis and treatment of haemophilia a patients
DE60142356D1 (en) 18480 HUMAN PROTEIN KINASEMOLEKÜLE AND ITS USES
WO2002013845A3 (en) Inflammation related g-protein coupled receptor
IL138585A0 (en) Vertebrate batched -2 protein
Elkon Ribosomal RNP
BR9810046A (en) Nucleotide sequence, expression vector, host cell, mammalian sperm protein, recombinant sperm protein, sperm protein 4, 1 and / or 6.7, pharmaceutical composition, and contraceptive vaccine

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]